成人费城染色体阳性急性淋巴细胞白血病达完全分子学缓解后异基因造血干细胞移植的效用
本研究纳入日本成人白血病研究组酪氨酸激酶抑制剂时代前瞻性临床研究中3个月内达完全分子学缓解的147例费城染色体阳性急性淋巴细胞白血病患者,比较首次完全缓解期接受(101例)与未接受(46例)异基因造血干细胞移植的结局,多因素分析显示移植与更优总生存和无复发生存相关,倾向性评分匹配分析证实该结果。
要点
- 3个月内达完全分子学缓解的Ph+ALL患者中,首次完全缓解期接受异基因移植与更优总生存(aHR 0.54)和无复发生存(aHR 0.21)相关
- 移植队列5年校正总生存73%、无复发生存70%,非移植队列分别为50%和20%
- 移植虽与非复发死亡升高相关(aHR 3.49),但与更低复发率相关(aHR 0.10)
核心结论
- 在3个月内达完全分子学缓解的Ph+ALL患者中,首次完全缓解期接受异基因造血干细胞移植较未移植队列有更优生存和更低复发。
- 倾向性评分匹配分析证实了多因素分析的结果。
研究设计与样本
- 比较Ph+ALL患者首次完全缓解期接受与未接受异基因造血干细胞移植的结局。
- 纳入日本成人白血病研究组酪氨酸激酶抑制剂时代前瞻性临床研究中3个月内达完全分子学缓解的患者。
- 共147例符合分析条件,其中异基因移植101例、非移植46例。
主要发现
- 多因素分析中,异基因移植与更优总生存显著相关(校正风险比0.54,95%CI 0.30-0.97,p=.04)。
- 多因素分析中,异基因移植与更优无复发生存显著相关(校正风险比0.21,95%CI 0.12-0.38,p<.001)。
- 异基因移植队列5年校正总生存73%、无复发生存70%,非移植队列分别为50%和20%。
- 异基因移植与非复发死亡升高相关(校正风险比3.49,95%CI 1.17-10.4,p=.03),但与更低复发率相关(校正风险比0.10,95%CI 0.05-0.20,p<.001)。
- 异基因移植与更优无移植物抗宿主病无复发生存相关(校正风险比0.43,95%CI 0.25-0.74,p=.002)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study aimed to investigate the usefulness of allogeneic stem cell transplantation (allo-SCT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) in the first complete remission (CR1) with complete molecular remission (CMR). We compared the outcomes between Ph+ALL patients who did or did not undergo allo-SCT in CR1. We included patients enrolled in the prospective clinical studies in the tyrosine kinase inhibitor era conducted by the Japan Adult Leukemia Study Group, who achieved CMR within 3 months. A total of 147 patients (allo-SCT: 101; non-SCT: 46) were eligible for this analysis. In the multivariate analyses, allo-SCT was significantly associated with both superior overall survival (OS) (adjusted hazard ratio (aHR): 0.54; 95% CI: 0.30-0.97; p = .04) and relapse-free survival (RFS) (aHR: 0.21; 95% CI: 0.12-0.38; p < .001). The 5-year adjusted OS and RFS were 73% and 70% in the allo-SCT cohort, whereas they were 50% and 20% in the non-SCT cohort. Despite the higher non-relapse mortality (aHR: 3.49; 95% CI: 1.17-10.4; p = .03), allo-SCT was significantly associated with a lower relapse rate (aHR: 0.10; 95% CI: 0.05-0.20; p < .001). In addition, allo-SCT was also associated with superior graft-versus-host disease-free, relapse-free survival (aHR: 0.43; 95% CI: 0.25-0.74; p = .002). Propensity score-matched analyses confirmed the results of the multivariate analyses. In patients who achieved CMR within 3 months, allo-SCT in CR1 had superior survival and lower relapse compared with the non-SCT cohort.
引用
- Nishiwaki S, Sugiura I, Fujisawa S, et al. Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete molecular remission. Am J Hematol. 2024. PMID: 38314662. doi:10.1002/ajh.27237
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。